NeurAxon Named One of Canada’s Top 10™ Life Science CompaniesNeurAxon Selected as Best Company Presentation in the Life Sciences Technologies Stream of the Banff Venture Forum

TORONTO, ON – October 14, 2010 – NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), has been named as one of Canada’s Top 10™ Life Science Companies and was also given the award for the Best Company Presentation in the Life Sciences Technologies Stream of the Banff Venture Forum.

“NeurAxon welcomes these recognitions of our ongoing work to develop a fundamentally new mechanism to address serious unmet needs and markets for a broad range of pain indications,” commented Lawrence E. Bloch, M.D., J.D., Chief Executive Officer of NeurAxon. “We are honored to be named among this elite group of Canadian companies and proud of our Canadian-based scientific team, whose efforts have generated a pipeline of first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), which offer potentially significant advantages over currently available pain therapeutics.”

About Canada’s Top 10™
Canada’s Top 10™ Life Science Companies are selected from a pool of entrants by an independent international jury of life science venture capitalists. Based on their expert knowledge of investment in the life science sector, the jury selects companies that offer the best investment and partnership prospects. Since its inception, competition alumni have secured more than $600M in venture capital financing. Further information is available at www.topcanadiancompanies.ca.

About Banff Venture Forum
Banff Venture Forum showcases early and growth stage companies in three streams: Information Technology, Energy Technology and Life Sciences Technology. The Life Sciences Technologies stream focuses on emerging companies developing and marketing cutting edge life sciences, biotechnology, medical devices, industrial life sciences and agricultural biotech products and services. Further information is available at www.banffventureforum.com.

About NeurAxon Inc.
NeurAxon, Inc. (www.neuraxon.com) discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.